Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06819007
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer” GOG 3112/ DSI-T-DXd ENHERTU (DO-01); DESTINY-Ovarian01 (DO-01)] DS8201-772
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study consists of two parts: Part 1 (safety run-in) and Part 2 (randomized part [like the flip of a coin]). The purpose of Part 1 is to learn more about the safety and tolerability of the...
-
NCT05640999
A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: Porter, ColoradoThis study is being done to answer the following question: Are there types of early-stage endometrial cancer that require less treatment than the usual approach? We are doing this study because we...
-
NCT05256225
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: Porter, Colorado -
NCT05611931
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this Phase 3 study is to compare the PFS of patients receiving Selinexor maintenance therapy after prior systemic therapy to the PFS of patients receiving placebo as maintenance therapy...
-
NCT05527184
IMGN151-1001: A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoWe are doing this study to test the safety and effectiveness of the test drug. The purpose of the study is to answer the following questions: What are the side effects of the test drug? At what dose...
-
NCT06072781
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05154487
A Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to find out if the combination of the drugs alpelisib and fulvestrant is better or worse than the usual approach for your type of cancer. The usual approach is defined as...
-
NCT05128825
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of Zn-C3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this Study includes the following: To test the safety of the Study drug and how you will feel while taking the Study drug. To find out what effects, good and/or bad, it has on you and...
-
NCT05256225
A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research...
-
NCT05281471
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoYou are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube...
-
NCT04291612
Sentinel Lymph Node Endometrial Cancer Trial: A Prospective Multicenter International Single-Arm Observational Trial (SELECT)
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoWe are doing this study to find out how often your type of cancer comes back (recurs) after the standard treatment. We also want to see how often the standard treatment results in a buildup of fluid...
-
Pilot Feasibility Study of the Interplay between the Host Gut Microbiome and Efficacy of Treatment for Epithelial Ovarian Cancer Patients Receiving IMmunotherapy
This study is currently enrolling.Associated Conditions: GynecologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis research is being done to see if your gut microbiome (microorganisms that live in the gut) could help as a biomarker of clinical response to immunotherapy.